[go: up one dir, main page]

JPH08169817A - Capsule - Google Patents

Capsule

Info

Publication number
JPH08169817A
JPH08169817A JP31452094A JP31452094A JPH08169817A JP H08169817 A JPH08169817 A JP H08169817A JP 31452094 A JP31452094 A JP 31452094A JP 31452094 A JP31452094 A JP 31452094A JP H08169817 A JPH08169817 A JP H08169817A
Authority
JP
Japan
Prior art keywords
capsule
film
chain
straight
glucan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP31452094A
Other languages
Japanese (ja)
Inventor
Noriyoshi Ono
知徳 小野
Tetsuo Miura
哲男 三浦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Capsule Co Ltd
Original Assignee
Fuji Capsule Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Capsule Co Ltd filed Critical Fuji Capsule Co Ltd
Priority to JP31452094A priority Critical patent/JPH08169817A/en
Publication of JPH08169817A publication Critical patent/JPH08169817A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PURPOSE: To obtain a capsule having excellent thermostability and high storage stability, by using a straight-chain β-1,3-glucan or a substance containing it as a film-forming base of the capsule. CONSTITUTION: This capsule comprises a straight-chain β-1,3-gulcan alone or the straight-chain β-1,3-gulcan and gelatin as a film-forming base. The capsule is coated with a film comprising the straight-chain β-1,3-gulcan or coated with a film containing the straight-chain β-1,3-gulcan. The capsule is usable in the field of medicine, food, cosmetic and health food. The straight-chain β-1,3-gulcan is a gelatinizing agent having a high thermal coagulating properties and produces a hard gel having high heat resistance and a degree of extremely low solubility when heated to a high temperature of >=80 deg.C. Consequently, since the straight-chain β-1,3-gulcan is used as a coating film for a capsule or for coating a capsule, thermostability in capsule processing is improved and wax requiring heating in the processing can be used as contents.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、医薬品、食品、化粧
品、健康食品等の分野において利用されるカプセル剤に
関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to capsules used in the fields of medicines, foods, cosmetics, health foods and the like.

【0002】[0002]

【従来の技術】従来、これらカプセル剤の皮膜基剤は、
主に溶解性、速効性に優れるゼラチンが主として使用さ
れている。
2. Description of the Related Art Conventionally, the film base of these capsules is
Gelatin, which has excellent solubility and fast-acting properties, is mainly used.

【0003】[0003]

【発明が解決しようとする課題】しかしながらゼラチン
を皮膜基剤とするカプセル剤は、耐熱性がないために、
製造時において40℃以上に加温された内容物のカプセ
ル剤加工は難しく、また溶解性が高いために胃内での溶
解を調節することができず徐放性や腸溶性を付与するこ
とが困難であった。また、製造後のカプセル剤は、吸湿
性に富むため包装作業中に相互付着を起こしたり、保存
中に容器に付着したりしやすい。高温下では内容物の漏
洩などをおこすことがあった。
However, since gelatin-based capsules do not have heat resistance,
During manufacturing, it is difficult to process the contents heated to 40 ° C or higher into capsules, and since the solubility is high, dissolution in the stomach cannot be controlled, and sustained release or enteric property may be imparted. It was difficult. In addition, since the manufactured capsules have a high hygroscopic property, they easily stick to each other during the packaging work or stick to the container during storage. At high temperatures, the contents may leak.

【0004】[0004]

【課題を解決するための手段】本願発明は、カプセル剤
の皮膜基剤として直鎖β−1,3−グルカン、若しくは
これを含むものをカプセル剤の皮膜基剤として使用する
こと、またはこれらでカプセル剤をコーティングするこ
とにより、上記の問題点を解決するためになされたもの
である。
According to the present invention, a straight-chain β-1,3-glucan, or one containing it, is used as a film base of a capsule, or a film base of a capsule is used. This is done in order to solve the above problems by coating a capsule.

【0005】本発明における直鎖β−1,3−グルカン
とは微生物(Alcaligenes faecalisvar. myxogenes
等)が生産する加熱凝固性発酵多糖類をいう。一般には
カードランとして市販されているものを用いることがで
きる。
The linear β-1,3-glucan in the present invention means a microorganism (Alcaligenes faecalis var. Myxogenes
Etc.) refers to a heat-coagulable fermentable polysaccharide. Generally, what is marketed as curdlan can be used.

【0006】カプセル剤の種類には、軟カプセル剤・硬
カプセル剤・マイクロカプセル剤等があり、それぞれ製
法が異なる。軟カプセル剤の製法としては打抜法・滴下
法、硬カプセル剤の製法としてはピン浸漬法、マイクロ
カプセル剤の製法としてはコアセルベーション法・スプ
レードライング法等がある。
There are soft capsules, hard capsules, microcapsules, and the like as the types of capsules, and their manufacturing methods are different. The soft capsule preparation method includes a punching / dropping method, the hard capsule preparation method includes a pin dipping method, and the microcapsule preparation method includes a coacervation method / spray drying method.

【0007】本願発明にかかるカプセル剤は、上記軟カ
プセル剤の製法のうちの滴下法、硬カプセル剤の製法、
マイクロカプセル剤の製法については従来装置をそのま
ま利用して製造することができる。この場合の直鎖β−
1,3−グルカンの配合量は特に制限されず、目的とす
るカプセル剤の性質によって適宜配合できる。具体的に
はカプセル剤の付着防止を目的とする場合には、カプセ
ル皮膜基剤に対して、直鎖β−1,3−グルカンを1〜
5%、耐熱性向上を目的とする場合には1〜10%、徐
放性付与を目的とする場合には1〜100%、それぞれ
配合するのが好適である。
The capsule according to the present invention comprises a dropping method among the above-mentioned soft capsule preparation methods, a hard capsule preparation method,
Regarding the method for producing the microcapsule, it can be produced by using the conventional apparatus as it is. Linear β- in this case
The blending amount of 1,3-glucan is not particularly limited, and can be appropriately blended depending on the properties of the intended capsule. Specifically, for the purpose of preventing adhesion of capsules, 1 to 3 of linear β-1,3-glucan is added to the capsule film base.
5%, 1 to 10% for the purpose of improving heat resistance, and 1 to 100% for the purpose of imparting sustained-release property are preferably blended.

【0008】一方、軟カプセル剤の製法のうち打抜法
(ロータリー式)においては、直鎖β−1,3−グルカ
ンのみからなる皮膜基剤では、カプセル剤の製造には適
さない。打抜法の装置図は図1に示す通りであり、厚さ
0.8mm前後の水溶性高分子からなる2枚のフィルム
Fがそれぞれ向かい合った別方向から、ダイロールDの
ロール間に連続的に導かれる。一方、セグメントCと定
量供給装置Aとを備えた内容物供給装置Bから1カプセ
ル剤あたりの定量の内容物が加温された2枚のフィルム
Fの間に間欠的に注入され、2個のダイロールDに設け
られている金型によって打ち抜かれつつ、セグメントC
によりフィルムFがヒートシールされることにより内容
物を含有する軟カプセル剤製品Eが成形される。従って
フィルムFにはヒートシール性がカプセル化の必須条件
であるが、直鎖β−1,3−グルカンによるフィルムは
その性質に欠け、単独の処方では不可能であった。そこ
で本願発明者らは直鎖β−1,3−グルカンと混合する
皮膜形成物質を種々検討した結果ヒートシール性の良好
な水溶性高分子であるゼラチンの添加が効果的であるこ
とを見いだした。この場合の直鎖β−1,3−グルカン
の配合量はその目的によって適宜選択すれば良いが、フ
ィルムFが良好なヒートシール性を保持していることが
条件であるため、好ましくはゼラチンに対して1〜10
%である。
On the other hand, in the punching method (rotary method) of the soft capsule manufacturing methods, a film base composed only of linear β-1,3-glucan is not suitable for manufacturing capsules. The device diagram of the punching method is as shown in FIG. 1, and two films F made of a water-soluble polymer having a thickness of about 0.8 mm are continuously faced between the rolls of the die roll D from different directions facing each other. Be guided. On the other hand, from the content supply device B including the segment C and the constant amount supply device A, a fixed amount of content per capsule is intermittently injected between the two heated films F, and While being punched by the die provided on the die roll D, the segment C
Thus, the film F is heat-sealed to form the soft capsule product E containing the contents. Therefore, the heat-sealing property is an essential condition for encapsulation in the film F, but the film made of the linear β-1,3-glucan lacks the property and cannot be prepared by the single formulation. Then, the inventors of the present application examined various film-forming substances mixed with linear β-1,3-glucan, and found that the addition of gelatin, which is a water-soluble polymer having good heat-sealing property, was effective. . In this case, the blending amount of the linear β-1,3-glucan may be appropriately selected according to the purpose, but it is preferable to use gelatin because the condition that the film F has good heat sealability is required. To 1 to 10
%.

【0009】また、この時のセグメントCの温度は、通
常のゼラチン皮膜の場合には35〜45℃に調整される
が、本法の場合は直鎖β−1,3−グルカンの配合量に
よって適宜調整することが必要であり、その範囲は、4
5〜60℃の範囲で調整するのが好適である。
Further, the temperature of the segment C at this time is adjusted to 35 to 45 ° C. in the case of a usual gelatin film, but in the case of this method, it depends on the blending amount of the linear β-1,3-glucan. It is necessary to adjust appropriately, and the range is 4
It is preferable to adjust in the range of 5 to 60 ° C.

【0010】直鎖β−1,3−グルカンをカプセル剤皮
膜の外側にコーティングする場合には、例えばコーティ
ングパンで一定量のカプセル剤を転動させながら、直鎖
β−1,3−グルカンの水または有機溶媒等分散溶液を
カプセル剤表面に噴霧する方法で行うことができる。ま
た、上記分散溶液中にカプセル剤を浸漬して引き上げた
後、乾燥することによっても可能である。この場合も直
鎖β−1,3−グルカン水分散液の濃度に制限はない
が、その作業性の面から、直鎖β−1,3−グルカンの
分散液の粘度が低いことが好ましく、具体的には1〜1
0%が望ましい。
When the linear β-1,3-glucan is coated on the outside of the capsule film, the linear β-1,3-glucan of the linear β-1,3-glucan can be prepared by rolling a certain amount of the capsule in a coating pan, for example. It can be carried out by a method of spraying a dispersed solution such as water or an organic solvent on the surface of the capsule. It is also possible to immerse the capsule in the above dispersion solution, pull it up, and then dry it. In this case as well, the concentration of the linear β-1,3-glucan aqueous dispersion is not limited, but from the viewpoint of workability, it is preferable that the viscosity of the linear β-1,3-glucan dispersion is low, Specifically 1 to 1
0% is desirable.

【0011】本発明のカプセル剤は、必要に応じて、皮
膜・内容物・コーティング膜中に、従来のカプセル剤と
同様に、可塑剤・着色剤・遮光剤・防腐剤・矯味剤・乳
化剤等の添加物を配合することができる。
If necessary, the capsule of the present invention can be used in the film, contents, and coating film in the same manner as in conventional capsules, such as plasticizers, colorants, light-shielding agents, preservatives, flavoring agents, emulsifiers, etc. Can be added.

【0012】[0012]

【作用及び効果】直鎖β−1,3−グルカンは加熱凝固
性のゲル化剤であり、80℃以上の高温にすると耐熱
性、難溶性の高い、固いゲルができるので、これをカプ
セル剤皮膜若しくはカプセル剤コーティングに利用する
ことにより、カプセル加工時の耐熱性が向上し、加工時
に加熱を要するロウ・硬化油等をも内容物とすることが
できる。保存安定性については、高温多湿下であっても
相互付着・容器付着・内容物の漏洩などが無くなりその
向上が期待できる。一方薬品等としてカプセル剤を服用
した場合、カプセル皮膜中の他の成分は溶解するもの
の、直鎖β−1,3−グルカンはマトリックス状に残留
し、溶解性を制御するために、カプセル剤に徐放性を付
与することができる。
[Functions and effects] Linear β-1,3-glucan is a heat-coagulable gelling agent, and when heated to a temperature of 80 ° C or higher, a hard gel with high heat resistance and poor solubility can be formed. By using it as a film or capsule coating, the heat resistance during capsule processing is improved, and wax, hardened oil, etc. that require heating during processing can be used as the content. Regarding storage stability, mutual adhesion, container adhesion, leakage of contents, etc. will be eliminated even under high temperature and high humidity, and improvement in storage stability can be expected. On the other hand, when a capsule is taken as a drug or the like, other components in the capsule film are dissolved, but the linear β-1,3-glucan remains in a matrix form, and the capsule is used to control the solubility. Sustained release can be imparted.

【0013】また、直鎖β−1,3−グルカン分散液を
カプセル剤にコーティングした場合には、カプセル剤表
面に直鎖β−1,3−グルカンの耐熱性フィルムが形成
され、カプセル剤皮膜中に直鎖β−1,3−グルカンを
配合した場合と同様の効果を付与することができた。
When the capsule is coated with the linear β-1,3-glucan dispersion, a heat-resistant film of linear β-1,3-glucan is formed on the surface of the capsule, and the capsule film is formed. The same effect as when the straight-chain β-1,3-glucan was blended therein could be provided.

【0014】[0014]

【実施例】以下に本発明の一例において実施例、実験例
を挙げて詳説する。
EXAMPLES Hereinafter, one example of the present invention will be described in detail with reference to examples and experimental examples.

【0015】実施例1 表1に示すような皮膜処方で軟カプセル剤製造用皮膜液
を調製した。検体Aについては、常法どおり、表1記載
の膜処方を混合溶解後、粘度を18,000cps(6
0℃)に調整して軟カプセル剤製造用皮膜液を得た。検
体Bについては、用いる水の一部に直鎖β−1,3−グ
ルカンを加え、カッターミキサーを用いて高速攪拌によ
り分散させ、残りの水にゼラチンとグリセリンを溶解し
たものに加えて混合溶解後、粘度を18,000cps
(60℃)に調製して軟カプセル剤製造用皮膜液を得
た。
Example 1 A coating solution for producing soft capsules was prepared according to the coating formulation shown in Table 1. As for the sample A, the film formulation shown in Table 1 was mixed and dissolved in a usual manner, and then the viscosity was adjusted to 18,000 cps (6
The temperature was adjusted to 0 ° C.) to obtain a film liquid for producing a soft capsule. For sample B, linear β-1,3-glucan was added to a part of the water used, dispersed by high speed stirring using a cutter mixer, and gelatin and glycerin were dissolved in the remaining water and mixed and dissolved. After that, the viscosity is 18,000 cps
It was adjusted to (60 ° C.) to obtain a film liquid for producing a soft capsule.

【0016】[0016]

【表1】 充填物質の温度とカプセル剤製造の関係試験
に供する検体A及びBのカプセル剤皮膜用溶液の配合例
を示す。 実験例1 実施例1で得られた皮膜液「検体A」・「検体B」を用
いて、ライナー社製ロータリー式カプセル剤製造装置に
てオーバル5型(一般的に使用される楕円球型のカプセ
ル剤、以下同じ)の植物油内包軟カプセル剤を製造し
た。その際、充填する植物油の温度を適宜変えて充填を
行った。本願発明にかかるカプセル剤は表2に示すとお
り従来品に比べて充填物質が高温であってもカプセル剤
形成が可能で、加工時の耐熱性に優れていることがわか
った。
[Table 1] The following is an example of the formulation of the capsule coating solution of the samples A and B to be subjected to the relationship test between the temperature of the filling material and the capsule manufacturing. Experimental Example 1 Using the coating liquids “Sample A” and “Sample B” obtained in Example 1, an oval 5 type (of commonly used ellipsoidal sphere type) was used in a liner rotary capsule manufacturing apparatus. Capsule, same as below) was produced. At that time, the temperature of the vegetable oil to be filled was appropriately changed to perform the filling. As shown in Table 2, it was found that the capsule according to the present invention can form a capsule even when the filling material is at a high temperature and is excellent in heat resistance during processing, as compared with the conventional product.

【0017】[0017]

【表2】 充填物質の温度とカプセル剤製造の関係試験
結果 〔評価記号の説明〕 ○…通常のカプセル剤同様、良好に成形・充填できた。
[Table 2] Relationship between filling material temperature and capsule manufacturing test results [Explanation of evaluation symbols] O ... Like the usual capsules, molding and filling could be performed well.

【0018】△…充填後、やや変形があったが、製造可
能であった。
Δ: There was some deformation after filling, but it was possible to manufacture.

【0019】×…充填直後に液洩れして製造不可能であ
った。
X: Liquid leakage occurred immediately after filling, and production was impossible.

【0020】実施例2 表3に示すような皮膜処方により、実施例1と同様にし
て軟カプセル剤製造用皮膜液「検体1」〜「検体5」を
調製した。得られた皮膜液を用いてライナー社製ロータ
リー式カプセル剤製造装置にてオーバル5型の植物油内
包軟カプセル剤を製造した。その際、充填する植物油の
温度は常温とした。
Example 2 By the same film formulation as shown in Table 3, the film liquids "Sample 1" to "Sample 5" for producing soft capsules were prepared in the same manner as in Example 1. Using the obtained coating solution, an oval 5 type vegetable oil-containing soft capsule was manufactured with a rotary capsule manufacturing device manufactured by Liner. At that time, the temperature of the vegetable oil to be filled was normal temperature.

【0021】また、「検体6」はフィルムコーティング
したカプセル剤であって、8%濃度の直鎖β−1,3−
グルカンの水分散液に検体1のカプセル剤を、浸漬し、
熱風乾燥することにより得た。
"Sample 6" is a film-coated capsule, which has a linear concentration of 8% linear β-1,3-
Dip the capsule of Sample 1 in an aqueous dispersion of glucan,
Obtained by hot-air drying.

【0022】[0022]

【表3】 崩壊時間の比較実験及び付着試験に供する検
体1から検体5のカプ 実験例2 実施例2にて得られた検体1〜6のカプセル剤を、第1
2改正日本薬局方に準じて崩壊試験を行った。結果は表
4に示すとおり、直鎖β−1,3−グルカンの配合量が
多いほど崩壊時間の延長が認められた。このことは直鎖
β−1,3−グルカンの配合量によりカプセル剤に任意
の溶解性を付与できることを示唆している。また、検体
6については他の検体に比して最も崩壊の延長が認めら
れた。
[Table 3] Caps of Specimen 1 to Specimen 5 to be subjected to disintegration time comparison experiment and adhesion test Experimental Example 2 The capsules of Samples 1 to 6 obtained in Example 2 were used as the first
2 A disintegration test was conducted according to the revised Japanese Pharmacopoeia. As shown in Table 4, the longer the disintegration time, the longer the linear β-1,3-glucan content. This suggests that the solubility can be imparted to the capsule by the amount of the linear β-1,3-glucan added. In addition, Sample 6 showed the longest disintegration as compared with the other samples.

【0023】[0023]

【表4】 崩壊時間の比較試験結果 実験例3 カプセル剤の高温多湿下の付着状況を試験するため検体
1〜検体6を6号規格サンプル瓶に各々10球入れ、4
0℃、75%Rh及び30℃、100%Rhにて開栓状
態で24時間保存後、以下の操作を行い、操作後サンプ
ル瓶から落下したカプセル剤の累積数を記録した。
[Table 4] Comparative test results of disintegration time Experimental Example 3 In order to test the adhesion condition of the capsule under high temperature and high humidity, 10 balls of each of Sample 1 to Sample 6 were put into a No. 6 standard sample bottle, and 4
After storing at 0 ° C., 75% Rh and 30 ° C., 100% Rh in an open state for 24 hours, the following operation was performed, and the cumulative number of capsules dropped from the sample bottle after the operation was recorded.

【0024】1. サンプル瓶を机上に静かに逆にして置
く。
1. Gently invert the sample bottle on the desk.

【0025】2. 1の操作後サンプル瓶を机上1cmの高
さから逆にして落とす。
After the operation of 2.1, the sample bottle is dropped from a height of 1 cm on the desk.

【0026】3. 2の操作後サンプル瓶を机上3cmの高
さから逆にして落とす。
After the operation of 3.2, the sample bottle is dropped from the height of 3 cm on the desk.

【0027】4. 3の操作後サンプル瓶を机上5cmの高
さから逆にして落とす。
After the operation of 4.3, the sample bottle is dropped from the height of 5 cm on the desk.

【0028】結果は表5に示すとおりサンプル瓶への付
着及びカプセル剤同士の相互付着は、直鎖β−1,3−
グルカンの配合量の増加に応じて改善されていることが
わかった。
The results are shown in Table 5, and the adhesion to the sample bottle and the mutual adhesion of the capsules to each other are linear β-1,3-
It was found that the improvement was observed in accordance with the increase of the glucan content.

【0029】[0029]

【表5】 付着試験結果 [Table 5] Adhesion test results

【0030】[0030]

【発明の効果】以上のように本願発明にかかるカプセル
剤は、その直鎖β−1,3−グルカンの加熱凝固性を利
用し、これをカプセル基剤またはカプセル剤皮膜に用い
るものである。以上のように本願発明は、耐熱性の向上
により高融点物質を内容物とすることを可能とし、高温
多湿下であっても保存安定性の高いカプセル剤を提供す
るものである。また、服用のカプセル剤にあっては任意
に徐放性を付与することができる。
As described above, the capsule according to the present invention utilizes the heat-coagulability of the linear β-1,3-glucan and uses it for the capsule base or capsule film. INDUSTRIAL APPLICABILITY As described above, the invention of the present application provides a capsule having a high melting point substance that can be used as a content due to improved heat resistance, and has high storage stability even under high temperature and high humidity. In addition, a sustained-release property can be optionally imparted to the capsule for administration.

【0031】一方、かかる効果をカプセル剤にコーティ
ングした場合には、カプセル剤表面に直鎖β−1,3−
グルカンの耐熱性フィルムが形成され、カプセル剤皮膜
中に直鎖β−1,3−グルカンを配合した場合と同様の
効果を付与することができた。
On the other hand, when such an effect is coated on a capsule, linear β-1,3- is formed on the surface of the capsule.
A heat-resistant film of glucan was formed, and the same effect as when the straight-chain β-1,3-glucan was blended in the capsule film could be imparted.

【図面の簡単な説明】[Brief description of drawings]

セル剤皮膜用溶液の配合例を示す。 A formulation example of the cell agent coating solution is shown below.

【図1】 ロータリー式カプセル剤製造装置要部FIG. 1 Main part of rotary type capsule manufacturing device

【符号の説明】[Explanation of symbols]

A.定量供給装置(ポンプ) B.内容物供給装置 C.セグメント D.ダイロール E.カプセル剤 F.フィルム(カプセル剤皮膜物質) A. Quantitative supply device (pump) B. Content supply device C. Segment D. Die roll E. Capsule F. Film (capsule film material)

─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───

【手続補正書】[Procedure amendment]

【提出日】平成7年3月13日[Submission date] March 13, 1995

【手続補正1】[Procedure Amendment 1]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0022[Name of item to be corrected] 0022

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0022】[0022]

【表3】 実験例2 実施例2にて得られた検体1〜6のカプセル剤を、第1
2改正日本薬局方に準じて崩壊試験を行った。結果は表
4に示すとおり、直鎖β−1,3−グルカンの配合量が
多いほど崩壊時間の延長が認められた。このことは直鎖
β−1,3−グルカンの配合量によりカプセル剤に任意
の溶解性を付与できることを示唆している。また、検体
6については他の検体に比して最も崩壊の延長が認めら
れた。
[Table 3] Experimental Example 2 The capsules of Samples 1 to 6 obtained in Example 2 were used as the first
2 A disintegration test was conducted according to the revised Japanese Pharmacopoeia. As shown in Table 4, the longer the disintegration time, the longer the linear β-1,3-glucan content. This suggests that the solubility can be imparted to the capsule by the amount of the linear β-1,3-glucan added. In addition, Sample 6 showed the longest disintegration as compared with the other samples.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 直鎖β−1,3−グルカンを皮膜基剤と
するカプセル剤。
1. A capsule containing straight-chain β-1,3-glucan as a film base.
【請求項2】 直鎖β−1,3−グルカン及びゼラチン
を含有する皮膜基剤からなるカプセル剤。
2. A capsule comprising a film base containing straight chain β-1,3-glucan and gelatin.
【請求項3】 直鎖β−1,3−グルカンからなるフィ
ルム、又は直鎖β−1,3−グルカンを含有するフィル
ムによりコーティングされたカプセル剤。
3. A capsule comprising a film of linear β-1,3-glucan or a film containing linear β-1,3-glucan.
JP31452094A 1994-12-19 1994-12-19 Capsule Pending JPH08169817A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP31452094A JPH08169817A (en) 1994-12-19 1994-12-19 Capsule

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31452094A JPH08169817A (en) 1994-12-19 1994-12-19 Capsule

Publications (1)

Publication Number Publication Date
JPH08169817A true JPH08169817A (en) 1996-07-02

Family

ID=18054276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP31452094A Pending JPH08169817A (en) 1994-12-19 1994-12-19 Capsule

Country Status (1)

Country Link
JP (1) JPH08169817A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054077A1 (en) * 2001-12-11 2003-07-03 Ceapro Inc. Cereal beta glucan compositions, methods of preparation and uses thereof
US7867513B2 (en) 2004-02-17 2011-01-11 Eisai R&D Management Co., Ltd. Soft capsule
JP4875769B2 (en) * 2008-09-26 2012-02-15 株式会社三協 Soft capsule manufacturing method and manufacturing apparatus thereof
KR20140134937A (en) * 2013-05-15 2014-11-25 (주)아모레퍼시픽 Lamella capsule and formation method of the lamella capsule
WO2022091797A1 (en) 2020-10-30 2022-05-05 株式会社細川洋行 Soft capsule storage container, soft capsule-containing storage container, and soft capsule laminate

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054077A1 (en) * 2001-12-11 2003-07-03 Ceapro Inc. Cereal beta glucan compositions, methods of preparation and uses thereof
JP2005513140A (en) * 2001-12-11 2005-05-12 セアプロ インク Cereal β-glucan composition, preparation method and use thereof
AU2002347165B2 (en) * 2001-12-11 2008-05-29 Ceapro Inc. Cereal beta glucan compositions, methods of preparation and uses thereof
US8632798B2 (en) 2001-12-11 2014-01-21 Ceapro Inc. Cereal β glucan compositions, methods of preparation and uses thereof
US7867513B2 (en) 2004-02-17 2011-01-11 Eisai R&D Management Co., Ltd. Soft capsule
JP4875769B2 (en) * 2008-09-26 2012-02-15 株式会社三協 Soft capsule manufacturing method and manufacturing apparatus thereof
US8572933B2 (en) 2008-09-26 2013-11-05 Sankyo Co., Ltd. Method for manufacturing soft capsule and apparatus for manufacturing the same
KR20140134937A (en) * 2013-05-15 2014-11-25 (주)아모레퍼시픽 Lamella capsule and formation method of the lamella capsule
WO2022091797A1 (en) 2020-10-30 2022-05-05 株式会社細川洋行 Soft capsule storage container, soft capsule-containing storage container, and soft capsule laminate
US12358690B2 (en) 2020-10-30 2025-07-15 Hosokawa Yoko Co., Ltd. Storage container for soft capsules, soft capsule-containing storage container, and laminate for soft capsules

Similar Documents

Publication Publication Date Title
US6375981B1 (en) Modified starch as a replacement for gelatin in soft gel films and capsules
EP1062274B1 (en) Polyvinyl alcohol compositions
Naharros‐Molinero et al. Shell formulation in soft gelatin capsules: design and characterization
KR101762460B1 (en) Acid resistant capsules
CA2380068C (en) Pullulan film compositions
AU726280B2 (en) Improvements in or relating to encapsulation
WO2000025760A1 (en) Process for producing hard capsule
JPH08208458A (en) Capsule film composition
JP2006526057A (en) Uniform and thermoreversible low viscosity polymannan gum film and soft capsule made therefrom
KR101401193B1 (en) Soft capsule coating
CA2563985A1 (en) Improved pullulan capsules
KR20100014618A (en) Non-animal derived soft capsule shell and soft capsule having the same
JPH08169817A (en) Capsule
JP5143024B2 (en) Brown film composition and method for preparing the same
CA2050599A1 (en) Encapsulation of active substances in starch
JPH0278613A (en) Soft capsules containing essential oils
JP2005137935A (en) Hard capsule and method for producing the same
US2846353A (en) Capsule and method of production
CN1794979A (en) Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom.
CN114617292A (en) Novel bead blasting wall material for cigarettes and preparation method thereof
JP2022075306A (en) Method for manufacturing soft capsule and soft capsule
JPH08245372A (en) Capsule agent
CN1791388A (en) Homogeneous, thermoreversible alginate films and soft capsules made therefrom
JPH0380930A (en) Composition of gelatin coating
JPH07145082A (en) Enteric capsule